IP Library › Granted Patent US 12,241,068
Granted Patent B2
US 12,241,068 · App. 17/055,387 · Granted Mar 4, 2025

CD79-specific chimeric antigen receptor

Inventors: Martin Pulé (London, GB); Shaun Cordoba (London, GB); Simon Thomas (London, GB); Shimobi Onuoha (London, GB); Mathieu Ferrari (London, GB)
Assignee: AUTOLUS LIMITED
C12N15/625A61K39/4611A61K39/4631A61K39/464411A61K39/464412A61K39/464413A61P35/00C07K14/7051C07K16/2803C12N5/0636C12N15/86A61K38/00A61K2239/13A61K2239/31C12N2740/10043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,068
App. No.
17/055,387
Granted
Mar 4, 2025
Kind
B2
Abstract

The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.

Claims (95)

1. A chimeric antigen receptor (CAR) which specifically binds the unspliced portion of the CD79B ectodomain shown as SEQ ID NO: 146 and which comprises an antigen-binding domain comprising:

a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:

(SEQ ID NO: 113)

CDR1 - GFTFSNAA;

(SEQ ID NO: 114)

CDR2 - IRTKPNNYAT;

(SEQ ID NO: 115)

CDR3 - TYYDGSSYAMDA;

and

a light chain variable region (VL) having CDRs with the following sequences:

(SEQ ID NO: 116)

CDR1 - QSLEYSDGYTY;

CDR2 - EVS;

(SEQ ID NO: 117)

CDR3 - FQATHDPYT;

or

b) a VH having CDRs with the following sequences:

(SEQ ID NO: 121)

CDR1 - GFTFSHTA;

(SEQ ID NO: 122)

CDR2 - IRIQPKNYAT;

(SEQ ID NO: 123)

CDR3 - TAAGFGFDY;

and

a VL having CDRs with the following sequences:

(SEQ ID NO: 124)

CDR1 - QSLEYSDGNTY;

CDR2 - EVS;

(SEQ ID NO: 125)

CDR3 - LQATHDPFT;

or

c) a VH having CDRs with the following sequences:

(SEQ ID NO: 113)

CDR1 - GFTFSNAA;

(SEQ ID NO: 114)

CDR2 - IRTKPNNYAT;

(SEQ ID NO: 129)

CDR3 - TADGGYGFDY;

and

a VL having CDRs with the following sequences:

(SEQ ID NO: 116)

CDR1 - QSLEYSDGYTY;

CDR2 - EVS;

(SEQ ID NO: 130)

CDR3 - FQGTHDPYT;

or

d) a VH having CDRs with the following sequences:

(SEQ ID NO: 113)

CDR1 - GFTFSNAA;

(SEQ ID NO: 114)

CDR2 - IRTKPNNYAT;

(SEQ ID NO: 115)

CDR3 - TYYDGSSYAMDA;

and

a VL having CDRs with the following sequences:

(SEQ ID NO: 116)

CDR1 - QSLEYSDGYTY;

CDR2 - EIS;

(SEQ ID NO: 117)

CDR3 - FQATHDPYT;

or

e) a VH having CDRs with the following sequences:

(SEQ ID NO: 136)

CDR1 - GFTFSNTA;

(SEQ ID NO: 122)

CDR2 - IRIQPKNYAT;

(SEQ ID NO: 123)

CDR3 - TAAGFGFDY;

and

a VL having CDRs with the following sequences:

(SEQ ID NO: 137)

CDR1 - QRLEYSDGNTY;

CDR2 - EVS;

(SEQ ID NO: 125)

CDR3 - LQATHDPFT;

or

f) a VH having CDRs with the following sequences:

(SEQ ID NO: 141)

CDR1 - GFTFSSAA;

(SEQ ID NO: 114)

CDR2 - IRTKPNNYAT;

(SEQ ID NO: 115)

CDR3 - TYYDGSSYAMDA;

and

a VL having CDRs with the following sequences:

CDR1-

(SEQ ID NO: 116)

QSLEYSDGYTY;

CDR2-

EVS;

CDR3-

(SEQ ID NO: 117)

FQATHDPYT.

2. The CAR according to claim 1 , which comprises an antigen binding domain selected from a scFv and, a Fab.

3. The CAR according to claim 1 , wherein the antigen-binding domain comprises a sequence selected from SEQ ID NO: 120, 128, 133, 135, 140 and 144.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2020
From: PULÉ, MARTIN; CORDOBA, SHAUN; THOMAS, SIMON; ONUOHA, SHIMOBI; FERRARI, MATHIEU
To: AUTOLUS LIMITED
Reel/Frame 054412/0127 →
Priority Claims (1)
GB 1807870 · May 15, 2018 · national
Continuity (1)
Related Publication 20220273710A1 · Sep 1, 2022
References Cited (37)
US 7052906B1 · Lawson et al. · 2006 [cited by applicant]
US 10457730B2 · Pule et al. · 2019 [cited by applicant]
US 20160296562A1 · Pule et al. · 2016 [cited by applicant]
US 20160362472A1 · Bitter et al. · 2016 [cited by applicant]
US 20170051308A1 · Morgan et al. · 2017 [cited by applicant]
US 20180044417A1 · Pule et al. · 2018 [cited by applicant]
US 20190038672A1 · Pule et al. · 2019 [cited by applicant]
US 20190177412A1 · Onuoha et al. · 2019 [cited by applicant]
US 20190330337A1 · Pule et al. · 2019 [cited by applicant]
US 20200140544A1 · Pule et al. · 2020 [cited by applicant]
WO WO2015075468A1 · 2015 [cited by applicant]
WO WO2015075469A1 · 2015 [cited by applicant]
WO WO2015075470A1 · 2015 [cited by applicant]
WO WO2015142675A2 · 2015 [cited by applicant]
WO WO2016102965A1 · 2016 [cited by applicant]
WO WO2016139487A1 · 2016 [cited by applicant]
WO WO2016151315A1 · 2016 [cited by applicant]
WO WO2016164731A2 · 2016 [cited by applicant]
WO WO2017009474A1 · 2017 [cited by applicant]
WO WO2017172981A2 · 2017 [cited by applicant]
WO WO2017216561A1 · 2017 [cited by applicant]
WO WO2017216562A1 · 2017 [cited by applicant]
WO WO2018226958A1 · 2018 [cited by applicant]
WO WO2019220109A1 · 2019 [cited by applicant]
U.S. Appl. No. 17/084,535, filed Oct. 29, 2020. [cited by applicant]
U.S. Appl. No. 17/054,670, filed Nov. 11, 2020. [cited by applicant]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” J. Gen. Virol. 82:1027-1041 (2001). [cited by applicant]
Dornan et al., “Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma,” Blood 114(13):2721-2729 (2009). [cited by applicant]
Fry et al., “CD22-CAR T Cells Induce Remissions in CD19-CAR Naive and Resistant B-ALL,” Nat Med 24(1):20-28 (2018). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2019/051331 dated Aug. 1, 2019. [cited by applicant]
Palanca-Wessels et al., “Satefy and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study,” Lance… [cited by applicant]
Polson et al., “Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma,” Blood 110:616-23 (2007). [cited by applicant]
Ruella et al., “Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies,” Journal of Clinical Investigation, 126(10):3814-3826 (2016). [cited by applicant]
Schneider et al., “A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines,” Journal for ImmunoTherapy of Cancer 5(1):17 pages (2017). [cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology, 196:901-917 (1987). [cited by applicant]
Haso et al., “Anti-CD22-Chimeric Antigen Receptors Targeting B Cell Precursor Acute Lymphoblastic Leukemia,” Blood, DOI: 10.1182/blood-2012-06-438002, ISSN 0006-4971, 121(7):1165-1174 (2013). [cited by applicant]
Zah, “T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells,” Cancer Immunology Research, 4(6):498-508 (2016). [cited by applicant]